Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment
2020 San Antonio Breast Cancer SymposiumNadia Harbeck, MD, of the University of Munich, discusses the first outcome data from the phase III ADAPT HR+/HER– trial, which combined both static and dynamic biomarkers to optimize the adjuvant therapy approach in patients with intermediate- or high-risk luminal early breast cancer (Abstract GS4-04).
Related Videos
Roisin M. Connolly, MD, on HR+ Advanced Breast Cancer: Endocrine Therapy and Entinostat
Roisin M. Connolly, MD, of University College Cork, discusses phase III results from the E2112 trial, which showed exemestane plus entinostat did not improve survival in arom...
Chirag Shah, MD, on Assessing DCIS Recurrence Risk
Chirag Shah, MD, of the Cleveland Clinic, discusses the impact of DCISionRT testing on radiation therapy recommendations for patients with ductal carcinoma in situ following ...
Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dos...
Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses study findings that showed mindfulness meditation and survivorship education may effectively red...
Elizabeth A. Mittendorf, MD, PhD, on Her Plenary Lecture: Local Regional Management Following Neoadjuvant Therapy
Elizabeth A. Mittendorf, MD, PhD, of Brigham and Women’s Hospital, summarizes her plenary talk, which featured the uncertainties in treatment knowle...
